Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma

JAMA. 2024 Sep 24;332(12):1013-1014. doi: 10.1001/jama.2024.14101.
No abstract available

Plain language summary

This JAMA Clinical Guidelines Synopsis summarizes the 2023 American Association for the Study of Liver Diseases practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

MeSH terms

  • Adolescent
  • Adult
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / epidemiology
  • Carcinoma, Hepatocellular* / etiology
  • Carcinoma, Hepatocellular* / therapy
  • Child
  • Child, Preschool
  • Fatty Liver, Alcoholic / complications
  • Fatty Liver, Alcoholic / therapy
  • Female
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / prevention & control
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / therapy
  • Humans
  • Incidence
  • Infant
  • Liver / diagnostic imaging
  • Liver / pathology
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / therapy
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / epidemiology
  • Liver Neoplasms* / etiology
  • Liver Neoplasms* / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging / standards
  • Practice Guidelines as Topic*
  • Primary Prevention / standards
  • Ultrasonography / standards
  • Young Adult

Substances

  • Hepatitis B Vaccines
  • Antiviral Agents